A

Alexion

Global biopharmaceuticals focusing on rare diseases

Facilities Engineer

Full-TimePosted on 10/23/2026Deadline 11/6/26
No salary listed
Mid
Bachelor's
Dublin, Ireland
In Person
Facilities OperationsFacilities Management

About the job

Requirements
  • A qualification in facilities management, engineering, business administration, or a related discipline, with relevant facilities experience.
  • Experience supporting facilities engineering or Facilities Management services in a cGMP pharmaceutical, biopharmaceutical, or similarly regulated environment.
  • Working knowledge of technical and engineering operations, building services, and recognised facilities-management practices.
  • Experience coordinating external suppliers and monitoring service delivery against agreed requirements.
  • Practical understanding of budgeting, purchase orders, accruals, and basic accounting or finance principles.
  • Proficiency in Microsoft Office and experience using digital reporting and information-management tools.
  • Awareness of facilities engineering principles, including mechanics and thermodynamics, and site systems such as HVAC, plumbing, building fabric, security, and waste management.
  • General awareness and practical application of cGMP, SOP, and SHE requirements relevant to facilities work, including documentation, data generation, review, and interactions with other functions.
  • Basic knowledge of vendor-management processes and policies; ability to communicate engineering and service requirements, monitor deliverables against expectations, and escalate issues appropriately.
  • Ability to identify digital solutions that improve facilities performance and efficiency and support structured learning and change management to encourage adoption.
  • Understanding of lean concepts applied to facilities activities and participation in structured problem-solving and level-zero improvement initiatives.
  • Ability to review varied data sets critically, identify less-obvious insights, connect information to the broader operating context, and make informed decisions within the role’s sphere of influence, escalating when required.
  • Ability to balance competing priorities, set realistic targets, define plans, milestones, and resources with a focus on quality, resolve problems promptly, anticipate risks, and make informed trade-offs.
  • Ability to communicate clearly, present information effectively, and collaborate proactively with cross-functional peers, leaders, and service partners.
  • Ability to challenge assumptions constructively, support innovation, remain open to change, and revise plans in response to evolving priorities.
  • Strong organisational, analytical, and problem-solving skills, with the ability to maintain effective delivery under changing operational demands.
Responsibilities
  • Manage assigned Facilities Management services and coordinate planned and reactive maintenance activities to maintain safe, compliant, and effective site operations.
  • Supervise site-based Facilities Management partners, monitor supplier performance, and ensure services meet defined quality, safety, cost, and schedule expectations.
  • Ensure the site Pest Control Programme is compliant, effective, and measurable against relevant conformance standards.
  • Complete annual reviews of facilities training curricula and ensure required Facilities Management training is completed on time.
  • Implement and maintain procedures for building fabric, structures, and workplace facilities in accordance with company standards.
  • Plan and coordinate furniture installations, refurbishments, office-space allocation, desk-utilisation reviews, and workplace standards.
  • Manage parking allocation, waste collection, cleanroom garment supply, and catering services, including service quality, stock availability, health, and nutrition requirements.
  • Establish and monitor key performance indicators, including Facilities Management Helpdesk response performance, to drive service improvement and ensure standards are met or exceeded.
  • Support facilities compliance monitoring, deviations, investigations, change controls, and timely closure of associated actions.
  • Ensure buildings and facilities services comply with applicable health and safety legislation, cGMP requirements, and site procedures.
  • Identify and implement practical sustainability opportunities across facilities services and building operations.
  • Use Smartsheet, Power BI, SharePoint, and other approved digital tools to improve data visibility, reporting efficiency, and information management.
  • Perform facilities analysis and forecasting, support budget planning, ensure purchase orders are in place, and complete monthly accruals in line with budget expectations.
  • Support maintenance, compliance monitoring, deviation management, audit readiness, validation, and lifecycle activities as directed.
  • Take ownership of continued learning and guide colleagues where additional expertise or support is needed.

About the company

Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1992

Get referred to Alexion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's July 2026 half-year revenue rose 9%, driven partly by Alexion's rare-disease growth.
  • Ultomiris gained FDA Priority Review on June 15, 2026 for IgAN, with Q4 2026 decision.
  • Koselugo's November 2025 adult NF1 approval and ALXN2220 phase 3 expand the pipeline.

What critics are saying

  • EmblemHealth's April 2025 Soliris antitrust suit targets patent settlements and biosimilar delays.
  • Soliris faces biosimilar erosion after March 2025, while Ultomiris still depends on C5-franchise switching.
  • Ultomiris carries meningococcal boxed warnings; a single fatal infection can trigger litigation and prescribing pullback.

What makes Alexion unique

  • Alexion pioneered complement biology, turning C5 inhibition into approved medicines since Soliris, 2007.
  • Ultomiris, Soliris, Strensiq, and Koselugo span hematology, nephrology, endocrinology, and oncology-adjacent rare diseases.
  • AstraZeneca's 2021 acquisition gives Alexion global commercialization scale and deeper trial funding.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

StartupTicker
Apr 9th, 2024
Clinical Success For Neurimmune

Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM.  Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM

Business Wire
Apr 1st, 2024
Voydeya™ Approved In The Us As Add-On Therapy To Ravulizumab Or Eculizumab For Treatment Of Extravascular Hemolysis In Adults With The Rare Disease Pnh

WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”

Business Wire
Mar 25th, 2024
Ultomiris® (Ravulizumab-Cwvz) Approved In The Us For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (Nmosd)

WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2

PharmiWeb
Nov 28th, 2023
Nice Endorses Only Approved Treatment For Ultra-Rare Wolman Disease For Children Diagnosed Under The Age Of Two: Interview Opportunity

Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease.  . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old